Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Light chain glycosylation provides diagnostic clues in CAD

Primary cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia. Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, outlines the study investigating the presence of post-translational glycosylation as a potential mechanism for IgM modification. Results show changes in the IgM immunoglobulin structure by post-translational glycosylation of light chains were significantly more common in patients with CAD compared with other IgM monoclonal gammopathies. The presence of light chain glycosylation can provide diagnostic clues and can be a potential therapeutic target. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.